Animal model: 3-months-old female wildtype mice (C57BL/6J) Surgery: Bilateral ovariectomy (Fig. 1A) ; 4 weeks later: standardized femur osteotomy stabilized with an external fixator (Fig. 1B , C) Treatment: Injections with 25 mg/kg BW Mdk-antibody (Mdk-Ab) or vehicle 2x/week for 3 weeks Analyses: 3-point-bending test (Fig. 1D) and µCT (Fig. 1E) The authors declare that no conflicts of interest exist.
Objectives
Clinical data demonstrated significantly impaired bone regeneration in postmenopausal osteoporotic patients [1] . The molecular mechanisms behind that are still unclear. Therefore, there is a high clinical need for new treatment strategies. One promising drug target molecule is the heparin-binding growth-and differentiation factor Midkine (Mdk), because: Ø Mdk is supposed to be a negative regulator of bone formation [ 
Results
Increased Mdk serum levels after fracture in OVX mice (Table 1) : Ø fracture-induced increase of Mdk in the serum of sham-operated mice at day 3 Ø significantly higher and prolonged expression of Mdk in the serum of OVX mice Ø significantly decreased Mdk serum levels after Mdk-Ab treatment C B A 
Antagonizing Mdk abolished OVX-induced impaired healing:
Ø OVX compromised fracture healing by decreased biomechanical competence and bone formation in the fracture callus Ø accelerated fracture healing after Mdk-Ab treatment in OVX mice Ø beta-catenin expression is regulated by OVX (ê) and Mdk-Ab (é) Increased bone mass in the intact skeleton after Mdk-Ab treatment:
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